Presentation is loading. Please wait.

Presentation is loading. Please wait.

GastroPanel Innovation Pentti Sipponen, MD, PhD Professor Biohit Oyj, Helsinki.

Similar presentations


Presentation on theme: "GastroPanel Innovation Pentti Sipponen, MD, PhD Professor Biohit Oyj, Helsinki."— Presentation transcript:

1 GastroPanel Innovation Pentti Sipponen, MD, PhD Professor Biohit Oyj, Helsinki

2 GastroPanel for the unmet need (1) Gastrointestinal disorders are  a growing medical, ethical and economic global problem  and they are among the most common types of complaints made to primary care physicians worldwide  and are associated with a substantial healthcare and economic burden

3 Despite being one of the world’s largest therapeutic areas  many of the diseases of the gastrointestinal tract are still poorly understood  and diagnosis and therapy options are far from optimal  leaving many patients dissatisfied with their current treatment GastroPanel for the unmet need (2)

4 In addition, the ageing of the population is accompanied by severe diseases  such as gastric, oesophageal and colorectal cancers as well as peptic ulcers, dementia, depression, polyneuropathy, heart attacks, strokes, anemia and osteoporosis  which are causing an increasing burden for well-being  and even a threat to sustainable health care GastroPanel for the unmet need (3)

5 Biohit’s mission is to alleviate and solve these huge medical and economic problems  and to become a leading supplier of unique diagnostic products and analyzing systems  as well as turnkey, comprehensive GastroPanel Laboratories  with special focus on the development of safe, ethical and cost-efficient diagnosis of diseases and cancer prevention of the gastrointestinal tract (www.biohit.com/Diagnostics/Product Brochures /GastroPanel Laboratories)www.biohit.com/Diagnostics/Product Brochures /GastroPanel Laboratories GastroPanel for the unmet need (4)

6 The prevalence of dyspepsia is 20-40% of whole population  Dyspepsia is not a specific symptom  Correct diagnosis is not possible by symptoms alone  Gastroscopy with biopsies or GastroPanel are the only diagnostic alternatives of very often symptomless atrophic gastritis (loss of glands and function of the stomach mucosa) caused by H.pylori infection or autoimmune disease  GastroPanel blood tests will help in rationalizing of the endoscopic investigations Dyspepsia and the physician

7 Simple and reliable blood biomarker examination for primary care  Safe, ethical cost-efficient stomach health test  Non-radioactive ELISA tests based on highly specific monoclonal antibodies - assays can be automatized avoiding human errors  GastroPanel: pepsinogens I and II, amidated gastrin-17, and H.pylori antibodies  Dyspetic patients: Enable reliable diagnosis of “healthy” stomach mucosa, H.pylori gastritis and atrophic gastritis with related risks, such as gastric and oesophageal cancer GastroPanel

8 Primary examination for physicians at Basic Health Care

9 Pepsinogen I or Pepsinogen I /II - biomarkers of corpus (oxyntic mucosa) Gastrin biomarker of antrum (antral G cells) H.pylori antibodies - biomarker of gastritis Biohit GastroPanel Examination – “Genuine Laboratory Test” Venous blood sample. Sample needs centrifugation and stabilizer Corpus Pylorus Antrum Esophagus

10 Amidated gastrin-17 Acid + - Gastrin – Acid – Feedback Control Mechanism Oxyntic (corpus) glands Antral (pyloric) D and G cells Food proteins +

11 Atrophic corpus gastritis: Low acid output and low serum pepsinogen I

12 GastroSoft computer program helps and assists in interpretation of the GastroPanel data

13 Healthy, normal stomach: No risk of gastric disorders. Gastroscopy does not give additional information from stomach. Non-atrophic H.pylori (Hp+) gastritis: High ulcer risk, low cancer risk. Gastroscopy may be helpful – decision by patient and physician. Atrophic gastritis (Hp+ or Hp-): High cancer risk, low ulcer risk. High risk of malabsorption of vitamin B12, calcium, iron and zinc. Unexpected malabsorption of pharmaceutical drugs. Stomach is acid-free – will be colonized with bacteria and fungi from oro-pharynx and gut. Gastroscopy is mandatory.

14 Healthy, normal stomach: All biomarkers are normal. Non-atrophic H.pylori (Hp+) gastritis: Only H.pylori antibody test is positive. Atrophic gastritis (AG) - (Hp+ or Hp-): PGI (  g/L) and/or PGI / PGII Mild AG: 50 - < <7 Moderate AG: 30 - < <5 Severe AG: <30 <3 Atrophic gastritis is limited to corpus alone if gastrin-17 is 10 pmol/L or more, otherwise atrophic gastritis is in both antrum and corpus (highest known risk condition for gastric cancer!)

15 Healthy, normal stomach: Immediate gastroscopy is unnecessary because the risks of gastric diseases are practically non-existing. Non-atrophic H.pylori (Hp+) gastritis: Patient and physician may decide of further treatment and examinations. Consider eradication of H.pylori! Atrophic gastritis (Hp+ or Hp-): Gastroscopy is mandatory because of the cancer risk. Eradication of H.pylori is necessary if present.

16 Healthy StomachH.pylori gastritisAtrophic gastritis GastroPanel examination No risks – gastroscopy not the first option Treatment of H.pylori and gastroscopy optional Gastroscopy necessary Developing populations (age 50 or more): 30% 50% 20% Developed populations (age 50 or more): 70% 25% 5%

17 Healthy StomachH.pylori gastritisAtrophic gastritis GastroPanel examination. “China study” on 81 patients No risks – gastroscopy not the first option Treatment of H.pylori and gastroscopy optional Gastroscopy necessary 9 (11%) 27 (33%) Mild: 34 (42%) Moderate: 8 (10%) Severe: 3 (4%)

18 ______________________________________________________________ Endoscopy histology (N of cases) Normal H.pylori AtrophicTotalgastritis GastroPanel Normal H.pylori gastritis Atrophic gastritis Total ”Kalixanda” population sample from Sweden ( Agreus et al ). Overall accuracy of GastroPanel 85%.

19 H.pyloriG-17PGI PGII Antrum Corpus EIUpmol/l microg/l microg/l 30 < N A3  PGI is low indicating that corpus is severely atrophic. This conclusion is supported by low PGI/PGII ratio and high G-17.  Amidated G-17 is high indicating that antrum in normal  No H.pylori antibodies. H.pylori infection is lost or atrophic gastritis is “autoimmune” of origin.  Gastroscopy is mandatory for cancer risk. Risks of malabsorption of vitamin B12, calcium (risk of osteoporosis), iron and zinc. Stomach is likely totally achlorhydric (no acid). GastroPanel - examples Severe atrophic gastritis in gastric corpus

20 H.pyloriG-17PGI PGIIAntrumCorpus EIUpmol/lmicrog/l microg/l 30 < NN  All GastroPanel biomarkers are normal  Risk of cancer or peptic ulcer is nil – irrespective of age.  Gastroscopy will not give any additional information. Colonoscopy or other clinical examinations are more useful. GastroPanel - examples Stomach mucosa is normal and healthy

21 Healthy versus diseased (”sick” gastric mucosa) : Tohoku – Japan: Accuracy : 94% Sensitivity: 95% Specificity: 93% Atrophic gastritis versus non-atrophic gastritis Kalixanda – Sweden: Accuracy:96% Sensitivity 71% Specificity 98% GastroPanel examination

22 Is stomach mucosa ”healthy” or ”sick”? GastroPanel provides diagnosis of H.pylori infection  but also gives the diagnosis of very often symptomless atrophic gastritis in corpus and/or antrum  with related risks, such as gastric and oesophageal cancer, peptic ulcer disease and the deficiency of vitamin B12, iron and calcium.  Atrophic gastritis is caused by H.pylori infection or autoimmune disease,  and diagnosed only by GastroPanel or gastroscopy

23 GastroPanel vs. Gastroscopy The quality of the gastroscopy is strongly dependent on the experience and competence of the gastroenterologist and the pathologist  GastroPanel doesn’t have such quality problems, irrespectively who ever does the GastroPanel blood tests  However, the diagnosis of atrophic gastritis obtained with GastroPanel is in good agreement with gastroscopy performed by skilful gastroenterologists and pathologists

24 H.pylori tests alone are useless and may result in malpractice 13C urea breath test, stool antigen test and antibody tests do not diagnose atrophic gastritis with related risks, such as gastric and oesophageal cancer 13C urea breath test and stool antigen test may give even 50% of false negative results in patient with atrophic gastritis, MALT lymphoma, bleeding peptic ulcer or in patients with PPI or antibiotic treatments GastroPanel does not include any of these serious medical and ethical problems

25 Serious Medical and Ethical Problems Malpractice and even unnecessary deaths, for example, due to gastric cancer and peptic ulcer bleedings  These serious medical and ethical problems of the “test-and-treat strategy” can be solved simply and economically  by omitting the 13C urea breath test, the stool antigen test or only antibody tests  and replacing them with the GastroPanel examination,  which provides abundant information of dyspepsia patients and healthy people for diagnosis and treatment

26 Enables non-endoscopic diagnosis and assessment of:  Gastritis and H.pylori (Hp) infection  Atrophic gastritis, both Hp+ and Hp-  Risk for gastric and oesophageal cancer and peptic ulcer dicease  Risk for malabsorption of vitamin B12 (dementia, depression, polyneuropathy), dietary calcium (osteoporosis) and iron (iron deficiency anemia) as well as some drugs  Hyperacid stomach: risks of the complications of gastroesophaceal disease, such as erosive oesophagitis and Barrett’s oesophagus  Healthy stomach GastroPanel from blood plasma

27 GastroSoft Interpretation

28 GastroPanel Laboratory  All GastroPanel microplate reagents: Pepsinogen I, Pepsinogen II, Gastrin-17 and H.pylori IgG ELISA kits  Vertical measurement principle based instruments; manual or automatic  Pipettes and disposable tips  Education and training  After sales and service support Brochures/GastroPanelLaboratories

29 The History of Biohit’s GastroPanel Innovation (1) The Finnish Gastritis Research Group, professors Max Siurala and Pentti Sipponen, and co- workers, on chronic gastritis and atrophic gastritis from the 70’s and 80’s  helped professors Barry J. Marshall and J. Robin Warren to realize that the infection and gastritis are connected to development of peptic ulcer diseases and stomach cancer

30 The History of Biohit’s GastroPanel Innovation (2) The Nobel Prize in Physiology or Medicine for 2005 jointly to Barry J. Marshall and J. Robin Warren for their discovery of "the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer disease" in 1982 (http://nobelprize.org/medicine/laureates/2005/press.html )

31 The History of Biohit’s GastroPanel Innovation (3) Professor Osmo Suovaniemi’s innovations, such as vertical measurement principle for micoroplates and very first microplate reader Titertek Multiskan, from the 60’s and 70’s, have  revolutionized microplate analyses worldwide and have been utilized so extensively and successfully since the 70’s, that they can justifiably be called global laboratory and industrial standards (www.google.com / Search “Osmo Suovaniemi vertical measurement principle”).  His innovations resulted, among other things, in rapid and massive development of reliable and safe non-radioactive microplate immunoassays,  on which the GastroPanel biomarker ELISA-tests (pepsinogen I and II, gastrin-17 and Helicobacter pylori antibodies) are based (www.biohit.com/About Us/History, / Diagnostics).www.biohit.com/About

32 Theranostic GastroPanel diagnosis and Acetium preventive treatment GastroPanel  Diagnose atrophic gastritis – Acid-free stomach: low PGI and/or low PGI/PGII and high G-17  Acid-free stomach is a risk factor of gastric and oesofageal cancer Acetium capsule  Binds and inactivates carcinogenic acetaldehyde (class 1 carcinogen for humans/WHO-IARC Oct 2009) in an acid-free stomach caused by atrophic gastritis or autoimmune disease

33 Thank You for Your Attention.


Download ppt "GastroPanel Innovation Pentti Sipponen, MD, PhD Professor Biohit Oyj, Helsinki."

Similar presentations


Ads by Google